There are plenty of reasons you might wonder, “What pill is this?” WebMD’s Pill Identifier can help you put a name to an unknown medication. It identifies prescription and over-the-counter ...

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...

Never take any medication you cannot positively identify. If you can't identify a pill and, thus, cannot take it, do not just let the medication sit on your shelf. Whether it's an over-the-counter ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...

The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal ...

Reaching for the first sleep aid you find when insomnia hits? Not all sleeping pills are the same. Each class of sleep aid works a bit differently from the other, and side effects vary.

People can’t stop talking about semaglutide (Ozempic, Wegovy), the buzzy diabetes and weight loss drug. Ozempic and Wegovy are injectable medications: Users prick themselves with a preloaded ...

As a daily pill-taker, I’ve learned that the phrase “Out of sight, out of mind” holds all too true when it comes to staying on top of my medications. A pill case that looks and feels nice ...

In conversation with experts, we’ll break down what you need to know about the most commonly prescribed type of contraception in the United States: the pill. “The most common and most familiar ...

The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.

Whether you’re interested in the pill, or you want to learn more about other forms of contraception (such as the implant, IUD or patch), there will never be a one-size-fits-all approach to ...